KALV — KalVista Pharmaceuticals Inc · catalysts, narrative & risks

Important framing: KALV is no longer a publicly traded asset (as of 2026‑10‑31)

The dominant fact to anchor on is that KalVista Pharmaceuticals ceased to be a public company on June 11, 2026, when Chiesi Group completed its takeover. KALV stopped trading on the Nasdaq Global Market as a result of the merger, and outstanding shares were cancelled and converted into the right to receive $27.00 per share in cash [1], [2], [3]. "Researching KALV as a publicly traded asset as of October 31, 2026" therefore means reviewing the terms and outcome of the acquisition that removed it from the public markets.